Search Thermo Fisher Scientific
The Applied Biosystems TrueMark SARS-CoV-2, Flu A, Flu B, RSV Select Panel is a multiplex real-time PCR solution that contains the assay and master mix needed for the simultaneous detection of RNA from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) in extracted human samples for research use only. Human ribonuclease P (RNase P) is included as an endogenous sample collection control.
Features of the TrueMark SARS-CoV-2, Flu A, Flu B, RSV Select Panel include:
• Single test for SARS-CoV-2, influenza A, influenza B, and RSV—detect and differentiate between disease states with similar symptoms while maintaining robust co-infection performance
• Multi-target assay design—multiple gene targets for SARS-CoV-2, flu A, flu B, and RSV to compensate for emerging mutations and variants and provide increased confidence in results
• Affordable and scalable—expand your respiratory sample testing while maintaining low operational costs and workflow simplicity
The TrueMark SARS-CoV-2, Flu A, Flu B, RSV Select Panel includes the TrueMark SARS-CoV-2, Flu A, Flu B, RSV assay mix and TrueMark 1‐Step Select Master Mix (No ROX) for simplified ordering. The kit can be used to quickly evaluate up to 200 samples and is validated for use with RNA extracted from anterior nares (AN) and nasopharyngeal (NP) swabs. The kit is recommended for use with the MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit, the KingFisher Flex Purification System, the QuantStudio 5 Real-Time PCR System (with 96-well, 0.2-mL block), and QuantStudio 5 Dx Real-Time PCR System (with 96-well, 0.2-mL block).
The TrueMark SARS-CoV-2, Flu A, Flu B, RSV Select Panel includes the following components:
• TrueMark SARS-CoV-2, Flu A, Flu B, RSV Assay Mix—multiplexed assay that contains primer and probe sets specific to SARS-CoV-2, Flu A, Flu B, RSV, and RNase P targets
• TrueMark 1‐Step Select Master Mix (No ROX)
Use this kit with:
• AcroMetrix Multi-Analyte SARS-CoV-2, Flu A/B, RSV A/B Control—inactivated SARS-CoV-2, influenza A/B, and respiratory syncytial virus A/B in proprietary viral transport media